Lombard Odier Asset Management Europe Ltd grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 38.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 69,585 shares of the medical research company’s stock after buying an additional 19,255 shares during the quarter. Lombard Odier Asset Management Europe Ltd’s holdings in IQVIA were worth $11,867,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors also recently modified their holdings of the company. J. Safra Sarasin Holding AG increased its holdings in IQVIA by 174.3% during the fourth quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock valued at $2,891,000 after buying an additional 8,151 shares during the last quarter. Franklin Street Advisors Inc. NC purchased a new position in shares of IQVIA during the 4th quarter worth $15,724,000. CWM LLC grew its position in shares of IQVIA by 23.9% during the 4th quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock valued at $12,585,000 after acquiring an additional 10,762 shares during the period. HF Advisory Group LLC grew its position in shares of IQVIA by 1,791.6% during the 4th quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock valued at $34,852,000 after acquiring an additional 146,444 shares during the period. Finally, Calamos Advisors LLC increased its stake in shares of IQVIA by 268.1% in the 4th quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.
Wall Street Analysts Forecast Growth
IQV has been the topic of several analyst reports. Robert W. Baird lifted their target price on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Wall Street Zen cut IQVIA from a “buy” rating to a “hold” rating in a research report on Saturday, June 27th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research note on Wednesday, June 17th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on IQVIA in a research report on Thursday, July 9th. Finally, Mizuho increased their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Thirteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $225.71.
IQVIA Stock Up 0.4%
IQV opened at $208.22 on Friday. The stock has a market cap of $34.75 billion, a price-to-earnings ratio of 25.80, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. The firm’s fifty day moving average is $188.23 and its 200 day moving average is $187.38. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $247.04.
IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion during the quarter, compared to analyst estimates of $4.10 billion. During the same quarter in the prior year, the business posted $2.70 EPS. IQVIA’s revenue for the quarter was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.
IQVIA announced that its Board of Directors has approved a share repurchase program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s leadership believes its stock is undervalued.
IQVIA Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Stories
- Five stocks we like better than IQVIA
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
